论文部分内容阅读
用随机对照方法评价了新菌灵250mg 2次/d疗程7～10d治疗上呼吸道感染20例;250～500mg 2次/d 疗程10～14d 治疗下呼吸道感染15例的安全有效性,获得了满意的临床疗效和细菌学结果。上、下呼吸道感染的痊愈率分别为95%与80%;细菌清除率分别为100%与93.33%;不良反应发生率仅为2.85%。新菌灵分别与头孢拉定和头孢克罗随机对照治疗上、下呼吸道感染,试验药与对照药的痊愈率、细菌清除率及不良反应发生率均无显著性差异。
A randomized controlled trial was conducted to evaluate the safety and efficacy of 250 mg twice a day for 7 days to 10 days for the treatment of upper respiratory tract infection with 250 mg twice daily for 250 mg to 500 mg for 10 days to 14 days. The clinical efficacy and bacteriological results. The cure rates of upper and lower respiratory tract infections were 95% and 80% respectively; the bacterial clearance rates were 100% and 93.33% respectively; the incidence of adverse reactions was only 2.85%. Neosamis, cefradine and cefaclor, respectively, randomized treatment of upper and lower respiratory tract infection, test drug and control drug cure rate, bacterial clearance rate and the incidence of adverse reactions no significant difference.